Diabetes

Type 2 Diabetes Variants Disrupt Function of SLC16A11 through Two Distinct Mechanisms.

Rusu V, Hoch E, Mercader JM, et al. Type 2 Diabetes Variants Disrupt Function of SLC16A11 through Two Distinct Mechanisms. Cell. 2017;170(1):199-212.e20. doi:10.1016/j.cell.2017.06.011Google Scholar DOI PubMed

Type 2 diabetes: genetic data sharing to advance complex disease research.

Flannick J, Florez JC. Type 2 diabetes: genetic data sharing to advance complex disease research. Nat Rev Genet. 2016;17(9):535-49. doi:10.1038/nrg.2016.56Google Scholar DOI PubMed

The genetic architecture of type 2 diabetes.

Fuchsberger C, Flannick J, Teslovich TM, et al. The genetic architecture of type 2 diabetes. Nature. 2016;536(7614):41-7. doi:10.1038/nature18642Google Scholar DOI PubMed

Inhibition of DYRK1A Stimulates Human β-Cell Proliferation.

Dirice E, Walpita D, Vetere A, et al. Inhibition of DYRK1A Stimulates Human β-Cell Proliferation. Diabetes. 2016;65(6):1660-71. doi:10.2337/db15-1127Google Scholar DOI PubMed

Impact of Common Diabetes Risk Variant in MTNR1B on Sleep, Circadian, and Melatonin Physiology.

Lane JM, Chang AM, Bjonnes AC, et al. Impact of Common Diabetes Risk Variant in MTNR1B on Sleep, Circadian, and Melatonin Physiology. Diabetes. 2016;65(6):1741-51. doi:10.2337/db15-0999Google Scholar DOI PubMed

Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants.

Hivert MF, Christophi CA, Franks PW, et al. Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants. Diabetes. 2016;65(2):520-6. doi:10.2337/db15-0950Google Scholar DOI PubMed

The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes.

Walford GA, Colomo N, Todd JN, et al. The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes. PLoS One. 2015;10(3):e0121553. doi:10.1371/journal.pone.0121553Google Scholar DOI PubMed

Identification of nuclear hormone receptor pathways causing insulin resistance by transcriptional and epigenomic analysis.

Kang S, Tsai LT, Zhou Y, et al. Identification of nuclear hormone receptor pathways causing insulin resistance by transcriptional and epigenomic analysis. Nat Cell Biol. 2015;17(1):44-56. doi:10.1038/ncb3080Google Scholar DOI PubMed

Loss-of-function mutations in SLC30A8 protect against type 2 diabetes.

Flannick J, Thorleifsson G, Beer NL, et al. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nat Genet. 2014;46(4):357-63. doi:10.1038/ng.2915Google Scholar DOI PubMed